excitingly, our studies of 5q in camptothecin (CCRF-CEM/C2) and mitoxantrone (HL-60/MX2) resistant cancer cells highlight its ability to selectively kill drug-resistant cells over parent cancer cells. 5q inhibits tumor cell growth through the induction of apoptosis, with detailed mechanism of its selectivity toward drug-resistant cancer cells under investigation. These results suggest that 5q is a promising
对当前疗法的多种耐药性的快速发展是癌症治疗中的主要障碍。因此,可以克服癌细胞中获得的耐药性的抗癌剂非常重要。以前,我们已经证明2-
氨基-4-(2-乙氧基-2-氧代乙基)-6-苯基-4 H-苯甲基-3-
羧酸乙酯(5a,sHA 14-1)是乙基2的稳定类似物-
氨基-6-
溴-4-(1-
氰基-2-乙氧基-2-氧代乙基)-4 H-苯甲基-3-
羧酸盐(6,HA 14-1),减轻耐药性并与多种癌症协同作用白血病细胞的疗法。5a的结构活性关系(
SAR)研究指导了乙基2-
氨基-6-(3',5'-二
甲氧基苯基)-4-(2-乙氧基-2-氧代乙基)-4的发展H - chromene -3-carboxylate(5q,CXL017),一种对多种血液学和实体瘤细胞具有低微摩尔细胞毒性的化合物。更令人兴奋的是,我们对
喜树碱(CCRF-C
EM / C2)和米托
蒽醌(HL-60 / MX2)耐药癌细胞中的5q的研究突显了